Cargando…

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis

BACKGROUND: The efficacy of dapagliflozin and empagliflozin in sodium-glucose cotransport-2 inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However, which drug could improve varied prognostic outcomes has not been elucidated. Hence, we compared their efficacies on the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Zepeng, Gao, Feng, Liu, Wei, He, Xuezhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013819/ https://www.ncbi.nlm.nih.gov/pubmed/35445086 http://dx.doi.org/10.3389/fcvm.2022.869272

Ejemplares similares

Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Pan, Deng, et al.
Publicado: (2021)

Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis
por: Xiang, Boyang, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
por: Ibrahim, Ayman, et al.
Publicado: (2020)

Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis
por: Zhang, Xuesong, et al.
Publicado: (2022)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
por: Tao, Wenqi, et al.
Publicado: (2023)

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2022)

Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials
por: Ma, Guang, et al.
Publicado: (2019)

The short-term efficacy of adventitial inversion with graft eversion anastomosis for the reconstruction of the aortic sinus in the root treatment of aortic dissection
por: Gao, Feng, et al.
Publicado: (2022)

Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
por: Jiang, Yaohui, et al.
Publicado: (2023)

Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region
por: Liao, Chia-Te, et al.
Publicado: (2021)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial
por: Chai, Ke, et al.
Publicado: (2023)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials
por: Gong, Bojun, et al.
Publicado: (2016)

Efficacy and safety of Puerarin injection on acute heart failure: A systematic review and meta-analysis
por: Li, Zunjiang, et al.
Publicado: (2022)

Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure: a meta-analysis
por: Chen, Shuai, et al.
Publicado: (2023)

Comparing Machine Learning Models and Statistical Models for Predicting Heart Failure Events: A Systematic Review and Meta-Analysis
por: Sun, Zhoujian, et al.
Publicado: (2022)

Comparative effectiveness of exercise training program in patients with heart failure: protocol for a systematic review of randomised controlled trials and network meta-analysis
por: Gao, Min, et al.
Publicado: (2021)

Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials
por: Guo, Hongxin, et al.
Publicado: (2023)

Traditional Chinese medicine injections for heart failure: a protocol for systematic review and network meta-analysis of randomised controlled trials
por: Lin, Shanshan, et al.
Publicado: (2020)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

A systemic review and meta-analysis comparing the ability of diagnostic of the third heart sound and left ventricular ejection fraction in heart failure
por: Dao, Lin, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Yu, Wanqian, et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure
por: Luo, Jin-Wen, et al.
Publicado: (2021)

Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts
por: Zhang, Hong, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

α-Linolenic Acid and Risk of Heart Failure: A Meta-Analysis
por: Wu, Jiandi, et al.
Publicado: (2022)

Safety and efficacy of His-Purkinje system pacing in the treatment of patients with atrial fibrillation and heart failure: a systematic review and meta-analysis
por: Guan, Lin, et al.
Publicado: (2023)

Comparing the efficacy and safety of medications in adults with hypertrophic cardiomyopathy: a systematic review and network meta-analysis
por: Mi, Keying, et al.
Publicado: (2023)

The Prevalence of Activities of Daily Living Impairment in Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Lu, Jing, et al.
Publicado: (2022)

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
por: Katzmann, Julius L., et al.
Publicado: (2022)

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value
por: Li, Xingxing, et al.
Publicado: (2022)

The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis
por: Yang, Chaojun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b3jurn0mrvqng6gm3gif4a6co1